Compare Amphastar Pharmaceuticals Inc (AMPH) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Select Medical Holdings Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Select Medical Holdings Corporation is far larger — about 2.5× Amphastar Pharmaceuticals Inc's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SEM | |
|---|---|---|
Market Cap | $826.08M | $2.05B |
Sector | Health | Health |
52-Week High | $30.81 | $16.66 |
52-Week Low | $16.87 | $11.77 |
Enterprise Value | $1.22B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following the company's recent acquisition by a consortium led by Robert A. Ortenzio at $16.50 per share. The stock shows mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company reported $5.45B revenue for 2025 with a 2.42% net margin, while valuation metrics appear reasonable with a P/E of 15.43 and P/S of 0.36. Recent earnings have been mixed with one beat and two misses against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the current price. While fundamentals show stable operations with positive cash flow from operations, multiple law firms are investigating potential fiduciary breaches in the buyout process. Analyst sentiment is mixed with 35.7% buy ratings, but the acquisition removes typical growth catalysts. Key risks include legal challenges to the merger terms and execution risks during the ownership transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
